Anti-Human NOTCH2 Recombinant Antibody (Tarextumab) (CAT#: TAB-H67)

Figure 1 Overall survival in the intent-to-treat population.

Red, tarextumab with gemcitabine and nab-paclitaxel; black, placebo with gemcitabine and nab-paclitaxel.

Hu, Z. I., Bendell, J. C., Bullock, A., LoConte, N. K., Hatoum, H., Ritch, P., ... & Strickler, J. (2019). A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer medicine, 8(11), 5148-5157.

Figure 2 Kaplan‐Meier analysis of overall survival in the intent-to-treat population divided by percentile.

OS for patients with ≥25th percentile Notch3 expression.

Hu, Z. I., Bendell, J. C., Bullock, A., LoConte, N. K., Hatoum, H., Ritch, P., ... & Strickler, J. (2019). A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer medicine, 8(11), 5148-5157.

Figure 3 Binding and blocking of OMP-59R5 to human and mouse Notch receptors.

OMP-59R5 blocks ligand binding to Notch2 and Notch3.

Yen, W. C., Fischer, M. M., Axelrod, F., Bond, C., Cain, J., Cancilla, B., ... & Tang, T. (2015). Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clinical cancer research, 21(9), 2084-2095.

Figure 4 OMP-59R5 blocks ligand binding to human and mouse Notch receptors.

Effect of OMP-59R5 on blocking human Notch2, and Notch3 signaling.

Yen, W. C., Fischer, M. M., Axelrod, F., Bond, C., Cain, J., Cancilla, B., ... & Tang, T. (2015). Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clinical cancer research, 21(9), 2084-2095.

Figure 5 Effect of OMP-59R5 on pancreatic CSC frequency and tumor recurrence after chemotherapy termination in OMP-PN8 xenograft tumors.

Yen, W. C., Fischer, M. M., Axelrod, F., Bond, C., Cain, J., Cancilla, B., ... & Tang, T. (2015). Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clinical cancer rearch, 21(9), 2084-2095.

Figure 6 OMP-59R5 inhibits significantly pancreatic CSC frequency and tumor recurrence in OMP-PN8 xenograft tumors.

Effect of OMP-59R5 on tumor recurrence followed by discontinuation of gemcitabine.

Yen, W. C., Fischer, M. M., Axelrod, F., Bond, C., Cain, J., Cancilla, B., ... & Tang, T. (2015). Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clinical cancer rearch, 21(9), 2084-2095.

Figure 7 Group mean concentration-time profiles. Data organized by nominal time; sample tested below LLOQ (lower limit of quantitation) were imputed to 1 μg/mL.

Smith, D. C., Chugh, R., Patnaik, A., Papadopoulos, K. P., Wang, M., Kapoun, A. M., ... & Tolcher, A. (2019). A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors. Investigational new drugs, 37(4), 722-730.

Figure 1 Anti-Human NOTCH2 Recombinant Antibody (TAB-H67) in FC

Flow cytometry analysis of U87 MG cells with purified antibody TAB-H67 (QCAb249, Blue). Cells were blocked with Human TruStain FcXTM and washed with 0.5% BSA-PBS. Cells were then incubated with TAB-H67 (5 μl/5x10^5 cells) for 60 min at 4°C. The secondary antibody was FITC anti-human IgG antibody (3 μl) for 60 min at 4°C.

Figure 2 Anti-Human NOTCH2 Recombinant Antibody (Tarextumab) (TAB-H67) in SDS-PAGE

SDS-PAGE analysis of TAB-H67 in reduced (Lane 1) and non-reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result, different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.

The purity of TAB-H67 was greater than 95% as determined by SDS-PAGE.

Figure 3 Anti-Human NOTCH2 Recombinant Antibody (Tarextumab) (TAB-H67) in HPLC

The purity of TAB-H67 was greater than 95% as determined by SEC-HPLC.

Figure 4 Anti-Human NOTCH2 Recombinant Antibody (Tarextumab) (TAB-H67) in WB

Western blot analysis of TAB-H67 was performed by loading Recombinant NOTCH2 protein.

TAB-H67 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-goat anti-human IgG
Lane 1: Reducing Antigen (0.1 μg)
Lane 2: Reducing Antigen (0.3 μg)
Lane 3: Reducing Antigen (0.6 μg)

Figure 5 Anti-Human NOTCH2 Recombinant Antibody (Tarextumab) (TAB-H67) in ELISA

ELISA analysis of TAB-H67 was performed by coating with Recombinant Human NOTCH2 Protein. Then blocked with BSA and incubated with Anti-Human NOTCH2 Recombinant Antibody (Tarextumab) (TAB-H67). The Goat Anti-Human IgG-HRP as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.